Free Writing Prospectus filed pursuant to Rule 433
Relating to the Preliminary Prospectus Supplement dated June 5, 2017 to the Prospectus dated November 22, 2016
Registration Statement No. 333-214756
US$250,000,000 Floating Rate Notes due 2022
Amended and Restated Final Term Sheet1
|Trade Date:||June 5, 2017|
|Settlement Date:||June 12, 2017 (T+5)|
|Expected Ratings:||Moody’s: A3 (stable); S&P: A- (negative)|
US$250,000,000 Floating Rate Notes due 2022:
|Security Type:||Senior Notes|
|Aggregate Principal Amount:||$250,000,000|
|Maturity Date:||June 10, 2022|
|Interest Rate:||For the first interest period, LIBOR as determined on June 8, 2017 plus the Spread. Thereafter, LIBOR as determined on the applicable Interest Determination Date (as defined below) plus the Spread.|
|Spread:||62 basis points|
|Price to Public:||100.000% of face amount|
|Interest Payment Dates:||March 10, June 10, September 10 and December 10 of each year, commencing September 10, 2017.|
|Interest Reset Dates:||March 10, June 10, September 10 and December 10 of each year, commencing September 10, 2017.|
Floating Rate Interest Periods
From and including an Interest Reset Date to but excluding the immediately succeeding Interest Reset Date (or the Maturity Date, if earlier).
Interest Determination Dates
Two London business days prior to each Interest Reset Date.
Gross Proceeds to Issuer:
|Underwriting Discount and Commissions:||0.350% of face amount|
|Net Proceeds to Issuer:||$249,125,000|
|Optional Tax Redemption:||In the event of various tax law changes and other limited circumstances that require the Company to pay additional amounts, in whole but not in part, at a price|
|1||Explanatory note: this Amended and Restated Final Term Sheet amends, restates and supersedes in its entirety AstraZeneca PLC’s Final Term Sheet dated June 5, 2017, only with respect to the section entitled “US$250,000,000 Floating Rate Notes due 2022”, to correct the Interest Determination Date for the first interest period as indicated opposite the caption “Interest Rate”.|
|equal to 100% of the principal amount plus accrued interest thereon to but excluding the redemption date.|
|Joint Book-Running Managers:||
Barclays Capital Inc.
HSBC Securities (USA) Inc.
Merrill Lynch, Pierce, Fenner & Smith Incorporated
Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. at toll-free 1-888-603-5847, HSBC Securities (USA) Inc. at toll-free 1-866-811-8049, Merrill Lynch, Pierce, Fenner & Smith Incorporated at toll-free 1-800-294-1322, or Morgan Stanley & Co. LLC at toll-free 1-866-718-1649.
Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system.